Skip to main content

Advertisement

SpringerLink
Log in

Dasatinib for chronic myelomonocytic leukemia with ZMIZ1-ABL1 fusion gene: a case report

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

The fusion gene ZMIZ1-ABL1 is rare, with only one known case reported in lymphatic system malignancies, and none reported in a myeloid tumor. Here, we report the case of a patient with chronic myelomonocytic leukemia with the ZMIZ1-ABL1 fusion gene. Elevated leukocytes and splenomegaly were the main manifestations. Remission was achieved with the second-generation tyrosine kinase inhibitor (TKI) dasatinib, and the response has been sustained for 10 months. The treatment results in this case suggest that dasatinib is effective in treating ZMIZ1-ABL1 fusion gene-positive disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The authors declare that data supporting the findings of this study are available within the article.

References

  1. Yadav V, Ganesan P, Veeramani R, Kumar VD. Philadelphia-like acute lymphoblastic leukemia: a systematic review. Clin Lymphoma Myeloma Leuk. 2021;21(1):e57–65. https://doi.org/10.1016/j.clml.2020.08.011.

    Article  CAS  PubMed  Google Scholar 

  2. De Braekeleer E, Douet-Guilbert N, Rowe D, Bown N, Morel F, Berthou C, et al. ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol. 2011;86(5):361–71. https://doi.org/10.1111/j.1600-0609.2011.01586.x.

    Article  CAS  PubMed  Google Scholar 

  3. Hantschel O. Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer. 2012;3(5–6):436–46. https://doi.org/10.1177/1947601912458584.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Soler G, Radford-Weiss I, Ben-Abdelali R, Mahlaoui N, Ponceau JF, Macintyre EA et al. Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation. Leukemia. 2008; 22(6):1278–80. https://doi.org/10.1038/sj.leu.2405033.

  5. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544.

    Article  CAS  PubMed  Google Scholar 

  6. Lee J, Beliakoff J, Sun Z. The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Res. 2007;35(13):4523–34. https://doi.org/10.1093/nar/gkm476.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Li X, Thyssen G, Beliakoff J, Sun Z. The novel PIAS-like protein hZimp10 enhances Smad transcriptional activity. J Biol Chem. 2006;281(33):23748–56. https://doi.org/10.1074/jbc.M508365200.

    Article  CAS  PubMed  Google Scholar 

  8. Pinnell N, Yan R, Cho HJ, Keeley T, Murai MJ, Liu Y, et al. The PIAS-like coactivator Zmiz1 is a direct and selective cofactor of Notch1 in T cell development and leukemia. Immunity. 2015;43(5):870–83. https://doi.org/10.1016/j.immuni.2015.10.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wang JY. Abl tyrosine kinase in signal transduction and cell-cycle regulation. Curr Opin Genet Dev. 1993;3(1):35–43. https://doi.org/10.1016/s0959-437x(05)80338-7.

    Article  CAS  PubMed  Google Scholar 

  10. Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res. 2009;33(8):1144–6. https://doi.org/10.1016/j.leukres.2009.03.011.

    Article  CAS  PubMed  Google Scholar 

  11. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–15. https://doi.org/10.1056/NEJMoa1403088.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Patnaik MM, Tefferi A. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(1):97–115. https://doi.org/10.1002/ajh.25684.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank the researchers and study participants for their contributions.

Author information

Authors and Affiliations

  1. Department of Hematology, the 940th Hospital of Joint Logistics Support Force of the Chinese People’s Liberation Army, 333 South Binhe Middle Road, Lanzhou, 730050, China

    Heng Liu, Hai Bai, Shuting Zhang, Xiaochen Zhao, Dongfeng Mao & Rui Xi

Authors
  1. Heng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hai Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuting Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaochen Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dongfeng Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rui Xi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rui Xi.

Ethics declarations

Competing interests

There are no financial disclosures relating to this manuscript and this research was conducted with no grant support or external assistance.

Ethics approval and consent to participate

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975 (in its most recently amended version). Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, H., Bai, H., Zhang, S. et al. Dasatinib for chronic myelomonocytic leukemia with ZMIZ1-ABL1 fusion gene: a case report. Int J Hematol 117, 929–932 (2023). https://doi.org/10.1007/s12185-023-03531-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-023-03531-z

Keywords

Search

Navigation